This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Current status and future perspectives in targeted therapy of NPM1-mutated AML
Leukemia Open Access 25 August 2022
-
Cancer nanotechnology: current status and perspectives
Nano Convergence Open Access 02 November 2021
-
A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
Microbiome Open Access 26 May 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
IMS Health. Press release (1 April). IMS Health reports U.S. prescription sales grew 5.1 percent in 2009, to $300.3 billion. IMS Health website [online], (2010).
Kerbel, R. S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171–1175 (2006).
Sawyers, C. L. Cancer: mixing cocktails. Nature 449, 993–996 (2007).
Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563–572 (2009).
Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).
Storey, S. Chronic myelogenous leukaemia market. Nature Rev. Drug Discov. 8, 447–448 (2009).
Bach, P. B. Limits on Medicare's ability to control rising spending on cancer drugs. N. Engl. J. Med. 360, 626–633 (2009).
WHO. Cancer. WHO website [online], (2010).
Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Approved targeted cancer therapies (PDF 69 kb)
Supplementary information S2 (table)
Expansion of indications for imatinib: US FDA approvals (PDF 61 kb)
Rights and permissions
About this article
Cite this article
Aggarwal, S. Targeted cancer therapies. Nat Rev Drug Discov 9, 427–428 (2010). https://doi.org/10.1038/nrd3186
Issue Date:
DOI: https://doi.org/10.1038/nrd3186
This article is cited by
-
Current status and future perspectives in targeted therapy of NPM1-mutated AML
Leukemia (2022)
-
Cancer nanotechnology: current status and perspectives
Nano Convergence (2021)
-
A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
Microbiome (2021)
-
Synthesis of pyrimido[1,2-a]indoles (minireview)
Chemistry of Heterocyclic Compounds (2021)
-
Current updates on precision therapy for breast cancer associated brain metastasis: Emphasis on combination therapy
Molecular and Cellular Biochemistry (2021)